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Plasmodium vivax is the only form of malaria indig-enous to South Korea (1); combination chloroquine 
and primaquine therapy has been the mainstay of vivax 
malaria treatment. After P. vivax reemerged after being 
eliminated in South Korea in the late 1970s, it mainly oc-
curred in soldiers or veterans stationed in the demilita-
rized zone between North Korea and South Korea. Be-
cause of this focus, mass chloroquine chemoprophylaxis 
has been administered in place for soldiers working in 
high-risk areas since 1997 (2,3). However, there is con-
cern that mass chemoprophylaxis might lead to reduced 
chloroquine susceptibility (2). In addition, soldiers were 
often given lower doses than that recommended by the 
World Health Organization (WHO); Commons et al. re-
ported that underdosing of chloroquine was associated 
with recurrence and increased parasite clearance time 
(PCT) (4). We studied the trends in South Korea during 
2000–2016 for treatment efficacy on the basis of PCT and 
fever clearance time (FCT). 
The Study 
We conducted this study in 4 hospitals in Goyang, 
Gyeonggi Province, and 1 hospital in Seoul. The 
study population consisted of patients >18 years of 
age in whom P. vivax malaria had been diagnosed 
during 2000–2016 and who had been prescribed chlo-
roquine alone or in combination with primaquine. 
We determined PCT, defined as the time in hours 
from chloroquine administration until the first blood 
smear negative for parasites after which the patient’s 
follow-up smears were also negative, from malaria 
smears taken daily in routine treatment of patients. 
To determine FCT, defined as the time from chloro-
quine administration until the patient’s body temper-
ature decreased to <37.5°C for 48 consecutive hours 
(5), we checked for fever every 4–6 hours or whenever 
the patient felt febrile. 
This study was approved by the local institution-
al review board. Statistical analyses were performed 
with SPSS Statistics 20 (IBM, https://www.ibm.com). 
For PCT and FCT, we reported median and inter-
quartile ranges (IQR) because Shapiro-Wilk test re-
sults showed that outcome measures did not follow a 
normal distribution. We compared trend analyses for 
PCT and FCT by enrollment periods using a linear-
by-linear association. 
We analyzed included data from a total of 1,199 
malaria cases over the 17-year study period. The 
mean (+SD) age of patients was 41.7 +14.2 years. 
None of the patients died of malaria during the study 
period; 44 relapsed. We divided the years of the study 
period into 3 ranges. During 2000–2005, 404 malaria 
cases occurred; that number increased to 566 during 
2006–2010, then decreased to 229 during 2011–2016. 
(Table 1). 
Median PCT increased from 63.0 hours dur-
ing 2000–2005 to 75.0 hours during 2011–2016 
(p<0.001). The proportion of patients whose PCT 
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We reviewed the clinical efficacy of chloroquine for Plas-
modium vivax malaria, the changing trend of parasite 
clearance time, and fever clearance time during 2000–
2016 in South Korea. Median parasite clearance time 
and fever clearance time increased significantly over the 
study period. Chloroquine was mostly underdosed when 
used to treat P. vivax malaria. 
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was >48 hours significantly increased over the 17 
years from 76.3% during 2000–2005 to 86.6% during 
2011–2016 (p = 0.03). In addition, the proportion of 
PCT at >72 hours also significantly increased from 
30.5% during 2000–2005 to 52.4% during 2011–2016 
(p = 0.005). 
We found fever in 1,074 (89.6%) of 1,199 patients 
at the time P. vivax malaria was diagnosed. Among 
those patients, median FCT increased from 28.0 hours 
during 2000–2005 to 48.0 hours during 2011–2016 
(p<0.001). The proportion of patients whose FCT was 
>48 hours increased from 17.6% during 2000–2005 to 
48.1% during 2011–2016 (p<0.001). The proportion of 
patients whose FCT was >72 hours also increased sig-
nificantly from 5.7% during 2000–2005 to 16.0% dur-
ing 2011–2016 (p = 0.001). 
All of the study patients were treated with either 
hydroxychloroquine or chloroquine phosphate. The 
mean total dose of chloroquine base administered 
was 23.0 mg/kg body weight in 838 patients (69.9%), 
which is less than the WHO-recommended target 
dose of 25 mg/kg. The trend of the mean of the total 
dose of chloroquine base decreased from 23.5 mg/kg 
during 2000–2005 to 22.1 mg/kg during 2011–2016 
(p<0.001). In addition, the proportion of patients re-
ceiving less than the WHO-recommended dose in-
creased from 68.8% during 2000–2005 to 77.3% during 
2011–2016 (p = 0.02).
Comparing patients with mean total chloro-
quine doses of >25 mg/kg or <25 mg/kg, we found 
that men were more likely than women to be in the 
<25 mg/kg group (84.2% vs. 44.9%; p<0.001) (Table 
2). Median FCT was longer in the <25 mg/kg group 
(65.0 h vs. 62.5 h; p = 0.02) and patients whose fever 
lasted >72 hours were more common in the <25 mg/
kg group (12.1% vs. 7.8%; p = 0.03). Relapse was also 
more common in this group (4.7% vs. 1.4%; p = 0.003). 
Conclusions
In this study, we made 2 important findings. First, the 
trend of increased PCT and FCT in South Korea might 
be ascribed to decreased P. vivax susceptibility to 
chloroquine that could be seen before the emergence 
of WHO-recognized drug resistance. Mass chemo-
prophylaxis of military personnel with hydroxychlo-
roquine started in 1997 in South Korea (3,6). Howev-
er, mass chemoprophylaxis with poor compliance to 
recommended dosing among the patients increased 
the possibility of chloroquine-resistant strains of P. 
vivax emerging. This finding may explain the failure 
of the prophylactic hydroxychloroquine treatment 
to widely protect South Korean army soldiers from 
P. vivax malaria by 2000, chloroquine-resistant cases 
occurring by the early to mid-2000s (7), and the in-
crease in PCT after chloroquine treatment since the 
late 2000s (2). 
Second, in areas with chloroquine-sensitive P. 
vivax, WHO recommends oral chloroquine at a total 
dose of 25 mg base/kg. Lower total doses are not rec-
ommended because they encourage the emergence 
of resistance (8). However, in the current study, 
≈70% of patients received a suboptimal dose (<25 
mg/kg) of chloroquine, partly because the total dose 
of chloroquine administered in South Korea was 
usually fixed at 1,500 mg base, as recommended by 
the US Centers for Disease Control and Prevention 
(9), rather than a weight-based dose. In our study, 
the average body weight of patients significantly 
 
Table 1. Demographic and clinical data for patients with Plasmodium vivax malaria, by study period, South Korea, 2000–2016* 
Variable 
Years 
p value 2000–2005, n = 404 2006–2010, n = 566 2011–2016, n = 229 
Age, y, mean (±SD) 40.5 ±14.3 42.5 ±14.0 41.6 ±14.6 0.06 
Sex     
 M  279 (69.1) 410 (72.4) 179 (78.2) 0.045 
 F 125 (30.9) 156 (27.6) 50 (21.8)  
Weight, kg, mean (±SD) 66.3 ± 0.57 68.4 ± 0.53 70.5 ± 0.88 <0.001 
Smear follow-up 131 (32.4) 168 (29.7) 82 (35.8) 0.23 
Median PCT (IQR), h 63.0 (49.0–82.0) 66.0 (56.3–78.0) 75.0 (52.0–96.5) <0.001 
 PCT >48 h 100/131 (76.3) 145/168 (86.3) 71/82 (86.6) 0.03 
 PCT >72 h 40/131 (30.5) 61/168 (36.3) 43/82 (52.4) 0.005 
Fever 347 (85.9) 521 (92.0) 206 (90.0) 0.04 
 Median FCT (IQR), h 28.0 (14.0–42.0) 43.0 (29.0–59.0) 48.0 (28.0–66.0) <0.001 
 FCT >48 h 49/279 (17.6) 198/477 (41.5) 87/181 (48.1) <0.001 
 FCT >72 h 16/279 (5.7) 54/477 (11.3) 29/181 (16.0) 0.001 
CQ, mg/kg, mean (±SD) 23.5 ±5.0 22.9 ±4.4 22.1 ±4.8 0.001 
 CQ <25 mg/kg 278 (68.8) 383 (67.7) 177 (77.3) 0.02 
Primaquine, mg/kg, mean (±SD) 0.23 ± 0.06 0.24 ± 0.06 0.29 ± 0.12 <0.001 
 Primaquine <0.25 265/373 (71.0) 343/543 (63.2) 114/221 (51.6) <0.001 
Relapse  9/394 (2.3) 20/541 (3.7) 10/220 (4.5) 0.20 
*Values are no. (%) patients/no. treated except as indicated. CQ, chloroquine; FCT, fever clearance time; IQR, interquartile range; PCT, parasite 
clearance time. 
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increased, from 66 kg during 2000–2005 to 71 kg dur-
ing 2011–2016 (p<0.001), but the recommended total 
fixed dose of chloroquine did not change. On the ba-
sis of the WHO recommendation of 25 mg/kg base, 
a total dose of chloroquine of 1,500 mg base would 
have been inadequate for patients whose body 
weight was >60 kg. In our study, we also found that 
relapse was more common in the <25 mg/kg chloro-
quine dose group (4.7% vs 1.4%; p = 0.003). 
This study has several limitations. First, parasite 
clearance was identified in only one third of study 
patients, but malaria smears were taken once dai-
ly, so clearance of parasites could have occurred at 
any hour in the interval between slides being taken, 
which could have affected the calculation of PCT. 
Second, temperature measurements might have been 
affected by the use of antipyretics and patients were 
not checked for fever hourly during hospitalization, 
either of which could have affected the calculation 
of FCT. Third, due to the retrospective nature of the 
study, we could not obtain other information that 
might affect estimates of PCT, such as patient vomit-
ing, which indicates that the medication may not have 
been absorbed normally, or FCT, such as duration of 
fever before malaria diagnosis. Prospective studies 
are needed to more accurately assess whether PCT or 
FCT has increased. 
In summary, increased PCT and FCT might be 
ascribed to reduced parasite susceptibility to chloro-
quine that could be seen before emergence of drug 
resistance in South Korea. Therefore, a proactive and 
continuous surveillance system for PCT and FCT is 
needed. In addition, chloroquine is mostly under-
dosed in the treatment of P. vivax malaria in South 
Korea; thus, clinicians should adhere to weight-based 
treatment guidelines. 
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From the Greek akantha (spike/thorn), which was added before amoeba 
(change) to describe this organism as hav-
ing a spine-like structure (acanthopodia). 
This organism is now well-known as Acan-
thamoeba, an amphizoic, opportunistic, and 
nonopportunistic protozoan protist widely 
distributed in the environment.
In 1930, it was reported by Castellani 
in yeast (Cryptococcus pararoseus) culture, 
and was later (1931) classified as the genus 
Acanthamoeba by Volkonsky. It was later 
found to be the etiologic agent of Acan-
thamoeba granulomatous encephalitis and 
keratitis in humans. This organism can also 
cause cutaneous acanthamebiasis in debili-
tated and immunocompromised patients.
Acanthamoeba [ǝˌ́́́́kæn.Өǝʹmi.bǝ]
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This scanning electron microscopic image shows an 
Acanthamoeba polyphaga protozoa about to complete 
the process of cell division known as mitosis, thereby 
becoming 2 distinct organisms. Note the numerous 
pseudopodia projecting from the surfaces of these 
organisms. These pseudopodia enable the amoebae 
to move about and grasp objects in their environment. 
Source: Centers for Disease Control and Prevention/
Catherine Armbruster, Margaret William; photograph, 
Janice Haney Carr, 2009.
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